Research Article
Compound Kushen Injection as an Adjunctive Therapy for the Treatment of Non-Small-Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials
Table 1
Characteristics of the 10 included studies.
| Study (year) | E/C | Intervention | CKI dosage (ml/day) | Duration | Outcome measures |
| Duan P. 2009 | 72/71 | CKI + GP vs. GP | 20 | NA | ➀➁➂➃ | Wang L. 2009 | 44/30 | CKI + DP/GP vs. TP/GP | 20 | 15–20 days/course, 2 courses | ➀➁➂➃ | Yuan X. R. 2010 | 53/56 | CKI + GEM vs. GEM | 20 | 4weeks/course, 4 courses | ➀➁➂➃ | Liu M. 2014 | 42/48 | CKI + NP vs. NP | 20 | 4 weeks/course, 4 courses | ➂➃ | Zhang J. J. 2015 | 42/42 | CKI + TP vs. TP | 20 | 3 weeks/course, 3 courses | ➀➂ | Zhang J. W. 2015 | 60/60 | CKI + GP vs. GP | 2 | 3 weeks/course, 2 courses | ➀➁➂ | Chen W. F. 2015 | 52/53 | CKI + GP/GP/TP vs. GP/GP/TP | 20 | 12 days/course, 2 course | ➀➁➂➃ | Zhang X. L. 2018 | 30/30 | CKI + TEG vs. TEG | 20 | 3 weeks/course, 4 courses | ➀➃ | Jia L. 2018 | 42/38 | CKI + PP vs. PP | 20 | 21 days/course, 1 course | ➀➁➂➃ | Zhang H. F. 2019 | 77/77 | CKI + TP vs. TP | 20 | 21 days/course, 2 courses | ➀➁➃ |
|
|
Note. E: experimental group; C: control group; CKI: compound kushen injection; NA: not available; DP: docetaxel + cisplatin; GP: gemcitabine + cisplatin; GEM: gemcitabine; NP: navelbine + cisplatin; PP: pemetrexed + carboplatin; TP: Taxol + cisplatin; TEG: tegafur; ➀: clinical efficiency; ➁: Karnofsky performance score; ➂: immune function; ➃: adverse reaction.
|